CoChat

Neurotrophin Signaling via TrkB and TrkC Receptors Promotes the Growth of Brain Tumor-initiating Cells

Open access
Lawn, Samuel, Krishna, Niveditha, Pisklakova, Alexandra, Qu, Xiaotao, Fenstermacher, David A., Fournier, Michelle, Vrionis, Frank D., Tran, Nam, Chan, Jennifer A., Kenchappa, Rajappa S., Forsyth, Peter A. · 2015 · Journal of Biological Chemistry
Cited by 140

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Neurotrophins and their receptors are frequently expressed in malignant gliomas, yet their functions are largely unknown. Previously, we have shown that p75 neurotrophin receptor is required for glioma invasion and proliferation. However, the role of Trk receptors has not been examined. In this study, we investigated the importance of TrkB and TrkC in survival of brain tumor-initiating cells (BTICs). Here, we show that human malignant glioma tissues and also tumor-initiating cells isolated from fresh human malignant gliomas express the neurotrophin receptors TrkB and TrkC, not TrkA, and they also express neurotrophins NGF, BDNF, and neurotrophin 3 (NT3). Specific activation of TrkB and TrkC receptors by ligands BDNF and NT3 enhances tumor-initiating cell viability through activation of ERK and Akt pathways. Conversely, TrkB and TrkC knockdown or pharmacologic inhibition of Trk signaling decreases neurotrophin-dependent ERK activation and BTIC growth. Further, pharmacological inhibition of both ERK and Akt pathways blocked BDNF, and NT3 stimulated BTIC survival. Importantly, attenuation of BTIC growth by EGFR inhibitors could be overcome by activation of neurotrophin signaling, and neurotrophin signaling is sufficient for long term BTIC growth as spheres in the absence of EGF and FGF. Our results highlight a novel role for neurotrophin signaling in brain tumor and suggest that Trks could be a target for combinatorial treatment of malignant glioma. Background: The role of Trk neurotrophin receptors in glioma is unknown. Results: TrkB and TrkC are required for survival of brain tumor-initiating cells in the absence of EGF and FGF. Conclusion: Trk receptors can control the survival of BTICs in the absence of EGF and FGF. Significance: Trks may be important targets for treatment of malignant gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.599373

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 140

Metadata

Authors
Lawn, S., Krishna, N., Pisklakova, A., Qu, X., Fenstermacher, D. A., Fournier, M., Vrionis, F. D., Tran, N., Chan, J. A., Kenchappa, R. S., & Forsyth, P. A.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2015-02
Volume
290
Issue
6
Pages
3814-3824
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2053654862
Cited by
140
References
9
FWCI
5.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurotrophin Signaling via TrkB and TrkC Receptors Promotes the Growth of Brain Tumor-initiating Cells. https://app.cochat.ai/papers/10.1074/jbc.m114.599373
The paper
Lawn, S., Krishna, N., Pisklakova, A., Qu, X., Fenstermacher, D. A., Fournier, M., Vrionis, F. D., Tran, N., Chan, J. A., Kenchappa, R. S., & Forsyth, P. A. (2015). Neurotrophin Signaling via TrkB and TrkC Receptors Promotes the Growth of Brain Tumor-initiating Cells. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m114.599373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.